ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0717

Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Christopher Xavier1, Kevin Byram2, Carol Langford3 and Michelle Ormseth4, 1Meharry Medical College, Nashville, 2Vanderbilt University Medical Center, Nashville, TN, 3Cleveland Clinic, Moreland Hills, OH, 4Vanderbilt University Medical Center, Nashville

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Micro-RNA, microbiome, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) is an autoimmune disease causing small vessel inflammation. Underlying mechanisms of disease are unclear, but the human microbiota may be a contributor. One way that bacteria can affect the immune system is through small RNAs (sRNAs), which are found abundantly in human circulation. The purpose of this study is to determine if circulating bacterial sRNAs are altered in patients with AAV compared to those with and without other inflammatory autoimmune diseases.

Methods: Patients with AAV were recruited from Vanderbilt University Medical Center (VUMC) and Cleveland Clinic. Participants with other inflammatory diseases (rheumatoid arthritis [RA] and systemic lupus erythematosus [SLE], termed here as “inflammatory control”) and control participants were recruited from VUMC. Total RNA was extracted from plasma from all participants and libraries were constructed for next-generation sequencing. sRNAs not aligning to the human genome with up to one mismatch were aligned to bacterial genomes in RefSeq using the TIGER pipeline. sRNA sequences and sRNA counts of bacterial taxa were compared using DESeq2 and the Benjamini-Hochberg method to adjust for multiple comparisons with false discovery rate at 5%.

Results: The study included 31 AAV, 20 inflammatory control (2 RA,18 SLE) and 4 control participants (Table 1). Examining sRNA counts of bacterial taxa, sRNAs aligning to 79 orders (which is the most specific taxonomy to which sRNAs can be assigned with confidence due to the short length and conserved sequences) were altered in AAV versus control and inflammatory control participants (Figure 1). Over half of the orders came from the phyla Pseudomonadota and Actinomycetota. Examining the sRNA sequences, 23 bacterial sRNAs were altered after multiple comparison adjustment in AAV versus control and inflammatory control participants (Figure 2). Of the 23 sequences, 21 were aligned to the phylum Pseudomonadota and all were either tRNA-derived RNAs (tDR) or ribosomal RNA-derived RNAs (rDRs). Among the altered sRNAs were 4 sRNAs with the same base sequence of GGGGCUGUAGCUCAGCUGGGA (thus having the same regulatory seed region, GGGCUGU). These sRNAs were predicted to downregulate key genes involved in T-cell activation and inflammatory processes, including ICOS/ICOSL, CTLA4, NFATC2, CASP3.

Conclusion: The plasma bacterial sRNA composition is altered in patients with AAV compared to control and inflammatory control participants, and the majority of altered sRNAs were from the phylum Pseudomonadota. Among altered bacterial sRNAs were several with a similar base sequence which was predicted to downregulate multiple genes that dappen immune responses, particularly via T cells. Thus, these sRNAs could promote autoimmune inflammation. Future mechanistic studies will be needed to confirm these findings.

Supporting image 1Table. Participant demographics

Supporting image 2Figure 1: Cladogram representing significantly altered phylum, class, and order level taxonomy of sRNA counts. Those order-level taxa counts with significant alteration (adjusted P value < 0.05) in both AAV versus control and versus inflammatory control participants were included.

Supporting image 3Figure 2: Volcano plots of altered plasma bacterial sRNAs in (A) AAV versus control and (B) AAV versus inflammatory control participants. Dots indicate one sRNA sequence with colored dots being those with a fold difference >1.5 and unadjusted p value < 0.05. (C) Venn diagram illustrating specific and common sRNA sequences altered in AAV versus controls and versus inflammatory controls after multiple comparison adjustment.


Disclosures: C. Xavier: None; K. Byram: None; C. Langford: AbbVie/Abbott, 12, Non-paid consultant, AstraZeneca, 5, 12, Non-paid consultant, Bristol-Myers Squibb(BMS), 5, 12, Non-paid consultant, GlaxoSmithKlein(GSK), 5, NS Pharma, 5; M. Ormseth: None.

To cite this abstract in AMA style:

Xavier C, Byram K, Langford C, Ormseth M. Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/circulating-bacterial-srnas-are-altered-in-patients-with-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-bacterial-srnas-are-altered-in-patients-with-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology